[ad_1] VANCOUVER, BC, Jan. 6, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company focused on revolutionizing women’s health, announces plans to complete preclinical studies […]
[ad_1] SINGAPORE, Dec. 8, 2024 /PRNewswire/ — A newly published collaborative study[1] in the Journal of Hepatology, featuring HistoIndex – a global leader in stain-free digital pathology solutions for managing fibrotic diseases – alongside Merck & Co., […]
[ad_1] Studies show promising new options to address unmet needs in sickle cell disease and immune thrombocytopenia SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — Researchers report significant progress toward expanding the therapeutic options available for people […]
[ad_1] 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) […]
[ad_1] Les résultats de l’essai clinique pourraient aider à sauver la vie de plus de 70 000 femmes enceintes dans le monde chaque année Selon l’Organisation mondiale de la santé (OMS), l’hémorragie puerpérale ou post-partum (HPP) est […]
